Other mutations observed in isolated cases included EGFR G721A, which has been shown to respond to Gefinitib or Erlotinib in non-small cell lung cancer [22] and PDGFRA H845Y which has been shown to respond to Imatinib [7]. Here, EGFR is linked to non-small cell lung carcinoma.